RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of ...

As 2024 concludes, here are 6 significant scientific discoveries, including medical breakthroughs, space exploration, and ...

Lenacapavir, a preventive HIV drug, could become accessible in low-income countries by 2026. Efforts spearheaded by global ...

Discover the new planets, moons, health advances, and ancient history uncovered in 2024.

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a ...

By 2025, a new HIV preventive drug, lenacapavir, could be available to the world's poorest regions. The Global Fund aims to ...

GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results.

A new long-acting preventive HIV drug could reach the world’s poorest countries by the end of 2025 or early 2026, a global ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

Lenacapavir is already approved for use as a treatment for multi-drug resistant HIV, costing around $42,250 for the first ...

The country is one of 18 others likely to get the Lenacapavir drug, which was proven to be 100 percent effective in ...

There is hope for a new 5 by 3 global target of getting 5 million people on long-acting PrEP to prevent HIV by 2030.